Health Condition 1: C260- Malignant neoplasm of intestinal tract, part unspecified
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
Dr. Reddy’s Laboratories Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: Male and female patients, = 18 years of age Histologically confirmed diagnosis of mCRC Patients who received bevacizumab, cetuximab, or panitumumab targeted therapies for the medical management of their disease in the first-line setting
Exclusion criteria
Exclusion criteria: Patients with follow-up data less than 6 months post-initiation of targeted therapies Patients whose treatment with targeted therapy began before 2015 or more recently than 30 days prior to the ethics committee approval
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical profile & tumor characteristics of mCRC patients Usage pattern of targeted therapies (bevacizumab, cetuximab, and panitumumab) in mCRC patients Overall Response Rate (ORR) Clinical Benefit Rate (CBR) Progression Free Survival (PFS) Duration of Response (DoR) Overall Survival (OS) Adverse drug reactions associated with targeted therapyTimepoint: Baseline and follow up as per routine clinical practice | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Rahul Rathod
Dr. Reddy’s Laboratories Ltd.
Outcome results
None listed